Patents Assigned to The Rockefeller University
  • Patent number: 11426379
    Abstract: A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-?, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: August 30, 2022
    Assignees: Provectus Pharmatech, Inc., The Rockefeller University
    Inventors: James G. Krueger, Sandra Garcet, Jamie Singer, Eric A. Wachter
  • Patent number: 11414422
    Abstract: 1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: August 16, 2022
    Assignee: The Rockefeller University
    Inventors: Lodoe Lama, Thomas Tuschl, Daisuke Tomita, Dinshaw Patel, J. Fraser Glickman, Taku Kamei, Michael Miller, Yasutomi Asano, Rei Okamoto, Shogo Hashizume, Jumpei Aida, Toshihiro Imaeda, Mayako Michino, Takanobu Kuroita
  • Publication number: 20220227844
    Abstract: This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
    Type: Application
    Filed: January 13, 2022
    Publication date: July 21, 2022
    Applicant: The Rockefeller University
    Inventors: Michel Nussenzweig, Zijun Wang
  • Publication number: 20220213114
    Abstract: Pyranoyrazoles and pyrazolopyridines of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Applicant: The Rockefeller University
    Inventors: Manish P. PONDA, Harold SELNICK, Melissa EGBERTSON, Jan L. BRESLOW
  • Patent number: 11377645
    Abstract: Provided are Cas9 enzymes that have mutations that enhance their properties, relative to un-mutated Cas9. The altered Cas9 enzymes exhibit i) an increased rate of spacer acquisition, or ii) increased cleavage efficiency of targets with NAG PAMs, or a combination of i) and ii). The altered Cas9 enzymes comprise an amino acid substitution of 1473 and K500 in a Streptococcus pyogenes or similar Cas9 enzyme. Also provided are polynucleotides, including expression vectors that encode the Cas9 enzymes, cells that contain the polynucleotides, and methods of making and using such cells. The disclosure includes tagging, or labelling bacteria, and for enhancing phage acquired immunity in bacteria, such as those used in industrial processes, including the food and beverage industry, such as the dairy industry. The food products are also included.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: July 5, 2022
    Assignee: The Rockefeller University
    Inventors: Luciano Marraffini, Robert Heller, David Bikard
  • Patent number: 11370830
    Abstract: Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 28, 2022
    Assignee: The Rockefeller University
    Inventors: Davide Robbiani, Michel Nussenzweig
  • Publication number: 20220195015
    Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.
    Type: Application
    Filed: November 4, 2021
    Publication date: June 23, 2022
    Applicant: The Rockefeller University
    Inventor: Michel Nussenzweig
  • Publication number: 20220185812
    Abstract: Tri-cyclyl nitrogen-containing heterocyclic compounds are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
    Type: Application
    Filed: March 12, 2020
    Publication date: June 16, 2022
    Applicants: The Rockefeller University, Memorial Sloan-Kettering Cancer Center
    Inventors: Daisuke TOMITA, Lodoe LAMA, Thomas TUSCHL, Dinshaw PATEL, J. Fraser GLICKMAN, Taku KAMEI, Michael MILLER, Yasutomi ASANO, Rei OKAMOTO, Shogo HASHIZUME, Jumpei AIDA, Toshihiro IMAEDA, Mayako MICHINO, Takanobu KUROITA
  • Publication number: 20220175988
    Abstract: A UV-C decontamination apparatus is used to decontaminate PPEs, such as respiratory masks. The apparatus is formed from a 3D printing process which makes the manufacture and use widespread. The apparatus includes a 3D printed chamber and a lid for enclosing the chamber. At least one UV-C lamp is supported in the chamber. Activation of the lamp is designed to decontaminate the mask supported in the chamber from the lid. An electronic switch assembly permits activation of the lamp only upon locking closure of a lid to the chamber. In a further embodiment, the hook is rotatable on the lid so as to rotate the mask in the chamber upon lamp activation.
    Type: Application
    Filed: December 6, 2021
    Publication date: June 9, 2022
    Applicant: The Rockefeller University
    Inventors: Alexander Epstein, Thomas P. Sakmar, Thomas Huber
  • Publication number: 20220169980
    Abstract: Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.
    Type: Application
    Filed: September 2, 2021
    Publication date: June 2, 2022
    Applicants: Memorial Sloan Kettering Cancer Center, The Rockefeller University
    Inventors: Lydia W.S. Finley, Bryce W. Carey, Craig B. Thompson, C. David Allis
  • Publication number: 20220169707
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Application
    Filed: October 13, 2021
    Publication date: June 2, 2022
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Ron Diskin, Anthony P. West, Michel Nussenzweig, Pamela J. Bjorkman
  • Patent number: 11339184
    Abstract: The present disclosure includes novel compounds useful as antimicrobial agents. The present disclosure further includes methods useful. The present disclosure further includes compositions and methods for treating or preventing a bacterial infection. The present disclosure further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: May 24, 2022
    Assignee: The Rockefeller University
    Inventors: Sean F. Brady, James Peek
  • Patent number: 11325966
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 10, 2022
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11325920
    Abstract: The present disclosure includes novel compounds useful as antimicrobial agents. The present disclosure further includes methods useful. The present disclosure further includes compositions and methods for treating or preventing a bacterial infection. The present disclosure further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 10, 2022
    Assignee: The Rockefeller University
    Inventors: Sean Brady, James Peek
  • Publication number: 20220135985
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Application
    Filed: October 18, 2021
    Publication date: May 5, 2022
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, The Rockefeller University
    Inventors: Feng Zhang, David Benjamin Turitz Cox, Luciano Marraffini, David Olivier Bikard, Wenyan Jiang, Neville Espi Sanjana
  • Publication number: 20220120686
    Abstract: A multi-photon imaging system includes a laser module having a first channel for outputting a two-photon excitation laser pulse and a second channel for outputting a three-photon excitation laser pulse. The system further includes a first optical path for guiding the two-photon laser pulse from the first channel of the laser module and a second optical path for guiding the three-photon laser pulse from the second channel of the laser module. A microscope is also provided for simultaneously receiving the two-photon laser pulse from the first optical path and the three-photon laser pulse from the second optical path, and simultaneously, or with well controllable delays, delivering the two-photon laser pulse and the three-photon pulse to a target volume. The system further includes a photodetector configured to collect photons generated within the target volume in response to simultaneous excitation of the target volume by both the two-photon laser pulse and the three-photon laser pulse.
    Type: Application
    Filed: January 30, 2020
    Publication date: April 21, 2022
    Applicant: The Rockefeller University
    Inventors: Alipasha VAZIRI, Siegfried WEISENBURGER
  • Patent number: 11299732
    Abstract: Provided are compositions and methods for cleaving a DNA sequence in a cell. The methods involve comprising introducing into a cell a recombinant vector containing a clustered regularly interspaced short palindromic repeats (CRISPR) system. The system includes a CRISPR RNA (crRNA) targeted to a DNA sequence in the cell that is operatively linked to a promoter; and CRISPR-associated enzymes (Cas) 10, Cas6, and at least one Csm protein. The Cas 10 cleaves the DNA sequence only during transcription of the DNA sequence that is operatively linked to the promoter. Also provided are recombinant vectors for modifying cells, cells that contain the recombinant vectors and modifications introduced by them, and kits that include the modified vectors.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 12, 2022
    Assignee: The Rockefeller University
    Inventors: Luciano Marraffini, Gregory Goldberg, Poulami Samai
  • Publication number: 20220054449
    Abstract: A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-?, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors.
    Type: Application
    Filed: September 3, 2021
    Publication date: February 24, 2022
    Applicants: The Rockefeller University, Provectus Pharmatech, Inc.
    Inventors: James G. Krueger, Sandra Garcet, Jamie Singer, Eric A. Wachter
  • Patent number: 11225524
    Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: January 18, 2022
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
  • Publication number: 20220002390
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Application
    Filed: September 9, 2021
    Publication date: January 6, 2022
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf